DOCSLIB.ORG

View of My Dissertation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View of My Dissertation THE ROLE OF MYOSIN VA AND THE DYNEIN/DYNACTIN COMPLEX IN NEUROFILAMENT AXONAL TRANSPORT DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By: Nael H Alami Graduate Program in Molecular, Cellular, and Developmental Biology The Ohio State University 2009 Dissertation Committee: Anthony Brown, Advisor Harold Fisk James Jontes Dale Vandre Copyright by Nael H Alami ABSTRACT Neurofilaments are the major cytoskeletal elements in mature neuronal cells. They are known for their space-filling properties and for forming an elastic network along the axons that is responsible for radial growth and maintaining proper caliber. Neurofilaments and other cytoskeletal polymers, membranous organelles, and macromolecular cargo are transported along the axon in one of two directions: away from the cell body, towards the axon tips, in an anterograde fashion, or back towards the cell body from the direction of the growth cones, in a retrograde fashion. The regulation of this transport is vital for the functional and structural well-being of the neuron and is mainly dependent on the microtubule- based motor proteins kinesins and dynein/dynactin. In 2002, a study by Rao et al. suggested a role for the actin-based motor protein myosin Va in neurofilament transport. They reported that myosin Va associates with neurofilaments in vivo and that neurofilaments accumulate in axons of neurons lacking myosin Va. Based on these observations, we hypothesize that myosin Va is involved in neurofilament transport and that in the absence of myosin Va, neurofilaments move less efficiently along the axons. To test this hypothesis, we used fluorescent live-cell imaging of neurofilament movement in ii SCG neurons from wild type and dilute lethal mice. Our results indicate that the absence of myosin Va from SCG neurons does not significantly alter neurofilament velocity or frequency of movement. We also used a fluorescence photoactivation pulse-escape technique to measure the rate of departure of photoactivatable GFP-tagged neurofilaments from photoactivated axonal regions in cultured DRG neurons from two strains of dilute lethal mice. We observed a 48%-169% increase in the mean time for neurofilaments to depart the activated regions in neurons from dilute lethal as compared to wild type. We conclude that neurofilaments pause for more prolonged periods in the absence of myosin Va. We propose that myosin Va is a short-range motor for neurofilaments and that it can function to enhance the efficiency of neurofilament transport in axons by delivering neurofilaments to their microtubule tracks. We also studied the role of dynein/dynactin in neurofilament transport. Dynein/dynactin is a retrograde motor complex that was found to associate with neurofilaments in vivo and in vitro. It has been previously proposed that it is responsible for retrograde neurofilament transport but without any direct evidence. We used SCG and cortical neuronal cultures to observe neurofilament transport in cells where dynein/dynactin activity has been disrupted using a number of different approaches that target different subunits of the complex. Using dynein heavy chain knock-down, dynein intermediate chain functional blocking antibody, dynamitin/p50 overexpression in SCG neurons and p150- coiled-coil1 overexpression in cortical neurons, we report an inhibition of iii retrograde transport. This clearly indicates that dynein/dynactin is indeed the retrograde neurofilament motor. We also observed a reciprocal inhibition of anterograde transport that mirrored the retrograde transport inhibition in every one of these manipulations. This suggests that a tight functional coupling exists between the retrograde and anterograde motors of neurofilaments, where the activity of one motor is needed for the activity of the other and vice versa. In one of our observations after disrupting dynein/dynactin activity using p150-coiled-coil overexpression in SCG neurons, we report an increase in anterograde transport. Our attempts to reproduce this result in cortical neurons, at different times after transfection, or with different transfection concentrations failed, as we observe an inhibition in both directions of transport in all such cases. This unique result, therefore, remains to be explored. In conclusion, we propose that the transport and organization of neurofilaments may be orchestrated by the coordinated activity of at least three different motor proteins, kinesins, dynein/dynactin, and myosin-Va, which act together to convey and distribute these polymers along neuronal axons, and the disruption of any of these motors could lead to neurofilament transport defects and accumulations that could ultimately result in neuronal degeneration. iv To my family v ACKNOWLEDGEMENTS First and foremost, I would like to thank my advisor Dr. Anthony Brown for his invaluable advice and support. The fruits of my work are a result of his supervision and guidance, and for that I am grateful. I would also like to thank my committee members, professors Harold Fisk, James Jontes and Dale Vandre for their patience, insightful suggestions and critical review of my dissertation. Past and present members of the Brown lab have helped make the work environment throughout those past years enjoyable and exciting. I would like to thank Dr. Niraj Trivedi for his friendship and continuous support, Dr. Atsuko Uchida, Lina Wang, Paula Monsma and Gulsen Colakoglu for their insightful critiques and encouragement when needed. Throughout my stay in Columbus I have been blessed by the presence of a group of very special and dear friends, whose support and love I will always cherish and treasure. You have made my journey profoundly enjoyable and memorable, sharing with me the good as well as the bad times. My thanks and gratitude go out to all of you, especially to Niraj, Alice, Erica, Nadine, Sleiman, Rami, Ihab, the lovely Nohal, my wonderful and inspirational friend Nesrine, my eternal friend Sarine, the beautiful Noura, and my second sister Zeina. vi Last but not least, this and everything I have and will accomplish, I owe to three people who have made me the person that I am: my father, whose every step has been a guiding light along the way; my mother, whose unconditional love inspires me to become a better person; and my talented, gentle and loving sister, Nadine. Your trust, belief, and unwavering support instill in me the strength and determination to carry on through all obstacles and hardship. To you, I am eternally grateful and indebted. vii VITA April 24, 1981………………………...…….Born- Mimess, Lebanon June 2001…………………………..………Bachelor of Science in Biology The American University of Beirut Beirut, Lebanon June, 2003…………………………………Master of Science in Biology The American University of Beirut Beirut, Lebanon September 2003-Present………………..PhD Candidate, Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Ohio, USA PUBLICATIONS Uchida A, Alami NH, Brown A. Tight functional coupling of kinein-1A and dynein motors in the bidirectional transport of neurofilaments. Mol Biol Cell. In press. Alami NH, Brown A. Myosin Va increases the efficiency of neurofilament transport by decreasing the duration of long-term pausing. J Neuroscience. 2009 May 20; 29(20):6625-34. viii FIELD OF STUDY Major Field: Molecular, Cellular and Developmental Biology ix TABLE OF CONTENTS Abstract ................................................................................................................ ii Acknowledgements ............................................................................................. vi Vita ..................................................................................................................... viii List of Tables ..................................................................................................... xiii List of Figures .................................................................................................... xiv Chapter 1: INTRODUCTION .................................................................................1 1.1. Neurofilaments............................................................................................1 1.1.1. General introduction .............................................................................1 1.1.2. Neurofilament organization and assembly ...........................................5 1.1.3. Neurofilament function .........................................................................8 1.2. Axonal transport........................................................................................13 1.2.1. A historical perspective ......................................................................13 1.2.2. Fast axonal transport..........................................................................15 1.2.3. Slow axonal transport.........................................................................16 1.2.4. Polymers vs monomers......................................................................18 1.2.5. Neurofilament phosphorylation and transport ....................................19 1.3. Neurofilaments and neurodegenerative disease ......................................22 1.3.1. Amyotrophic lateral sclerosis..............................................................23 1.3.2. Alzheimer’s disease ...........................................................................25 1.3.3. Parkinson’s disease ...........................................................................26
Load more

Recommended publications
  • Supplemental Material Table of Contents
    Supplemental material Table of Contents Detailed Materials and Methods ......................................................................................................... 2 Perioperative period ........................................................................................................................... 2 Ethical aspects ................................................................................................................................... 4 Evaluation of heart failure ................................................................................................................. 4 Sample preparation for ANP mRNA expression .................................................................................. 5 Sample preparation for validative qRT-PCR (Postn, Myh7, Gpx3, Tgm2) ............................................ 6 Tissue fibrosis .................................................................................................................................... 7 Ventricular remodeling and histological tissue preservation ................................................................ 8 Evaluation of the histological preservation of cardiac tissue ................................................................ 9 Sample preparation and quantitative label-free proteomics analyses .................................................. 10 Statistical methods ........................................................................................................................... 12 References ........................................................................................................................................
    [Show full text]
  • Genome-Wide Analyses Identify KIF5A As a Novel ALS Gene
    This is a repository copy of Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/129590/ Version: Accepted Version Article: Nicolas, A, Kenna, KP, Renton, AE et al. (210 more authors) (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 97 (6). 1268-1283.e6. https://doi.org/10.1016/j.neuron.2018.02.027 Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Genome-wide Analyses Identify KIF5A as a Novel ALS Gene Aude Nicolas1,2, Kevin P. Kenna2,3, Alan E. Renton2,4,5, Nicola Ticozzi2,6,7, Faraz Faghri2,8,9, Ruth Chia1,2, Janice A. Dominov10, Brendan J. Kenna3, Mike A. Nalls8,11, Pamela Keagle3, Alberto M. Rivera1, Wouter van Rheenen12, Natalie A. Murphy1, Joke J.F.A. van Vugt13, Joshua T. Geiger14, Rick A. Van der Spek13, Hannah A. Pliner1, Shankaracharya3, Bradley N.
    [Show full text]
  • Disrupted Neuronal Trafficking in Amyotrophic Lateral Sclerosis
    Acta Neuropathologica (2019) 137:859–877 https://doi.org/10.1007/s00401-019-01964-7 REVIEW Disrupted neuronal trafcking in amyotrophic lateral sclerosis Katja Burk1,2 · R. Jeroen Pasterkamp3 Received: 12 October 2018 / Revised: 19 January 2019 / Accepted: 19 January 2019 / Published online: 5 February 2019 © The Author(s) 2019 Abstract Amyotrophic lateral sclerosis (ALS) is a progressive, adult-onset neurodegenerative disease caused by degeneration of motor neurons in the brain and spinal cord leading to muscle weakness. Median survival after symptom onset in patients is 3–5 years and no efective therapies are available to treat or cure ALS. Therefore, further insight is needed into the molecular and cellular mechanisms that cause motor neuron degeneration and ALS. Diferent ALS disease mechanisms have been identi- fed and recent evidence supports a prominent role for defects in intracellular transport. Several diferent ALS-causing gene mutations (e.g., in FUS, TDP-43, or C9ORF72) have been linked to defects in neuronal trafcking and a picture is emerging on how these defects may trigger disease. This review summarizes and discusses these recent fndings. An overview of how endosomal and receptor trafcking are afected in ALS is followed by a description on dysregulated autophagy and ER/ Golgi trafcking. Finally, changes in axonal transport and nucleocytoplasmic transport are discussed. Further insight into intracellular trafcking defects in ALS will deepen our understanding of ALS pathogenesis and will provide novel avenues for therapeutic intervention. Keywords Amyotrophic lateral sclerosis · Motor neuron · Trafcking · Cytoskeleton · Rab Introduction onset is about 10 years earlier [44]. As disease progresses, corticospinal motor neurons, projecting from the motor cor- Amyotrophic lateral sclerosis (ALS) is a fatal disease char- tex to the brainstem and spinal cord, and bulbar and spinal acterized by the degeneration of upper and lower motor motor neurons, projecting to skeletal muscles, degenerate.
    [Show full text]
  • The Universal Mechanism of Intermediate Filament Transport
    bioRxiv preprint doi: https://doi.org/10.1101/251405; this version posted January 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 The universal mechanism of intermediate filament transport. 2 3 Amélie Robert1, Peirun Tian1, Stephen A. Adam1, Robert D. Goldman1 and Vladimir I. Gelfand1* 4 5 1Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern 6 University, Chicago, IL 60611, USA. 7 8 *Corresponding author. 9 Address: Department of Cell and Molecular Biology, Feinberg School of Medicine, 10 Northwestern University, 303 E. Chicago Ave. Ward 11-100, Chicago, IL 60611-3008 11 E-mail address: [email protected] 12 Phone: (312) 503-0530 13 Fax: (312) 503-7912 14 15 1 bioRxiv preprint doi: https://doi.org/10.1101/251405; this version posted January 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 16 ABSTRACT 17 Intermediate filaments (IFs) are a major component of the cytoskeleton that regulates a wide 18 range of physiological properties in eukaryotic cells. In motile cells, the IF network has to adapt 19 to constant changes of cell shape and tension. In this study, we used two cell lines that express 20 vimentin and keratins 8/18 to study the dynamic behavior of these IFs.
    [Show full text]
  • Neurofilaments and Neurofilament Proteins in Health and Disease
    Downloaded from http://cshperspectives.cshlp.org/ on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Neurofilaments and Neurofilament Proteins in Health and Disease Aidong Yuan,1,2 Mala V. Rao,1,2 Veeranna,1,2 and Ralph A. Nixon1,2,3 1Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York 10962 2Department of Psychiatry, New York University School of Medicine, New York, New York 10016 3Cell Biology, New York University School of Medicine, New York, New York 10016 Correspondence: [email protected], [email protected] SUMMARY Neurofilaments (NFs) are unique among tissue-specific classes of intermediate filaments (IFs) in being heteropolymers composed of four subunits (NF-L [neurofilament light]; NF-M [neuro- filament middle]; NF-H [neurofilament heavy]; and a-internexin or peripherin), each having different domain structures and functions. Here, we review how NFs provide structural support for the highly asymmetric geometries of neurons and, especially, for the marked radial expan- sion of myelinated axons crucial for effective nerve conduction velocity. NFs in axons exten- sively cross-bridge and interconnect with other non-IF components of the cytoskeleton, including microtubules, actin filaments, and other fibrous cytoskeletal elements, to establish a regionallyspecialized networkthat undergoes exceptionallyslow local turnoverand serves as a docking platform to organize other organelles and proteins. We also discuss how a small pool of oligomeric and short filamentous precursors in the slow phase of axonal transport maintains this network. A complex pattern of phosphorylation and dephosphorylation events on each subunit modulates filament assembly, turnover, and organization within the axonal cytoskel- eton. Multiple factors, and especially turnover rate, determine the size of the network, which can vary substantially along the axon.
    [Show full text]
  • Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic
    Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • Mutations in the Profilin 1 Gene Cause Familial Amyotrophic Lateral Sclerosis
    Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis Chi-Hong Wu, University of Massachusetts Claudia Fallini, Emory University Nicola Ticozzi, IRCCS Istituto Auxologico Italiano Pamela J. Keagle, University of Massachusetts Peter C. Sapp, University of Massachusetts Katarzyna Piotrowska, University of Massachusetts Patrick Lowe, University of Massachusetts Max Koppers, University Medical Centre Utrecht Diane McKenna-Yasek, University of Massachusetts Desiree M. Baron, University of Massachusetts Only first 10 authors above; see publication for full author list. Journal Title: Nature Volume: Volume 488, Number 7412 Publisher: Nature Publishing Group | 2012-08-23, Pages 499-+ Type of Work: Article | Post-print: After Peer Review Publisher DOI: 10.1038/nature11280 Permanent URL: https://pid.emory.edu/ark:/25593/rq3d5 Final published version: http://dx.doi.org/10.1038/nature11280 Copyright information: © 2012 Macmillan Publishers Limited. All rights reserved. Accessed September 30, 2021 3:27 PM EDT HHS Public Access Author manuscript Author Manuscript Author ManuscriptNature. Author ManuscriptAuthor manuscript; Author Manuscript available in PMC 2013 February 22. Published in final edited form as: Nature. 2012 August 23; 488(7412): 499–503. doi:10.1038/nature11280. Mutations in the Profilin 1 Gene Cause Familial Amyotrophic Lateral Sclerosis Chi-Hong Wu1, Claudia Fallini2, Nicola Ticozzi3, Pamela J. Keagle1, Peter C. Sapp1, Katarzyna Piotrowska1, Patrick Lowe1, Max Koppers4, Diane McKenna-Yasek1, Desiree M. Baron1, Jason E. Kost1, Paloma Gonzalez-Perez1, Andrew D. Fox1, Jenni Adams1, Franco Taroni5, Cinzia Tiloca3,6, Ashley Lyn Leclerc1, Shawn C. Chafe7, Dev Mangroo7, Melissa J. Moore8, Jill A. Zitzewitz9, Zuo-Shang Xu9, Leonard H. van den Berg4, Jonathan D. Glass10, Gabriele Siciliano11, Elizabeth T.
    [Show full text]
  • Molecular Diagnosis of Inherited Peripheral Neuropathies by Targeted Next-Generation Sequencing: Molecular Spectrum Delineation
    Open access Research BMJ Open: first published as 10.1136/bmjopen-2018-021632 on 28 October 2018. Downloaded from Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation Juliette Bacquet,1 Tanya Stojkovic,2 Amandine Boyer,1 Nathalie Martini,1 Frédérique Audic,3 Brigitte Chabrol,3 Emmanuelle Salort-Campana,4,5 Emilien Delmont,4 Jean-Pierre Desvignes,5 Annie Verschueren,4 Shahram Attarian,4,5 Annabelle Chaussenot,6 Valérie Delague,5 Nicolas Levy,1,5 Nathalie Bonello-Palot1,5 To cite: Bacquet J, Stojkovic T, ABSTRACT Strengths and limitations of this study Boyer A, et al. Molecular Purpose Inherited peripheral neuropathies (IPN) represent diagnosis of inherited a large heterogenous group of hereditary diseases with peripheral neuropathies by ► First study concerning patients with inherited pe- more than 100 causative genes reported to date. In this targeted next-generation ripheral neuropathies in South of France. context, targeted next-generation sequencing (NGS) sequencing: molecular spectrum ► New single-nucleotide variation mutations important delineation. BMJ Open offers the opportunity to screen all these genes with high for the scientific and medical community. 2018;8:e021632. doi:10.1136/ efficiency in order to unravel the genetic basis of the ► New copy number variations detected by the analy- bmjopen-2018-021632 disease. Here, we compare the diagnostic yield of targeted sis of next-generation sequencing data. NGS with our previous gene by gene Sanger sequencing ► Prepublication history and ► Lack of power (123 patients). additional material for this strategy. We also describe several novel likely pathogenic ► Lack of functional validation of variants of unknown paper are available online.
    [Show full text]
  • Mrna Transport in Dendrites: RNA Granules, Motors, and Tracks
    The Journal of Neuroscience, July 5, 2006 • 26(27):7139–7142 • 7139 Mini-Review mRNA Transport in Dendrites: RNA Granules, Motors, and Tracks Nobutaka Hirokawa Department of Cell Biology and Anatomy, Graduate School of Medicine, University of Tokyo, Hongo, Tokyo 113-0033, Japan The targeting of mRNAs to neuronal dendrites is an important protein sorting mechanism. Recent studies have revealed that mRNAs are transported by molecular motors. The kinesin superfamily protein KIF5 transports mRNAs such as calcium/calmodulin-dependent kinase II␣ (CaMKII␣) and Arc mRNAs along microtubules in large granules containing proteins involved in RNA transport, protein synthesis, RNA helicases, heterogeneous nuclear ribonucleoproteins (hnRNPs), and RNA-associated proteins. This transport is funda- mental to local protein synthesis and to the regulation of neuronal function. Key words: microfilament; tubulin; transport; granule; RNA trafficking; intracellular signaling; cytoskeleton Intracellular transport in neurons 45 members in mice and humans. Whereas kinesin superfamily Neurons have a highly polarized cell structure and typically con- proteins (KIFs) typically move toward the plus end of microtu- tain one long, thin filamentous axon and multiple dendrites that bules and participate in anterograde transport, cytoplasmic dy- differ from one another morphologically and functionally. Axons neins are minus-end-directed motors and mediate retrograde and dendrites differ in their intracellular signaling cascades and transport from axonal or dendritic terminals to the cell body. trafficking pathways. A consensus view is that proteins destined Many membranous organelles are transported from the cell for axons and presynaptic terminals are synthesized in the cell body and down the axon to the presynaptic terminal. KIF1A and body and transported down the axon in membranous organelles KIF1B␤ transport synaptic vesicle precursors containing synaptic or protein complexes.
    [Show full text]
  • Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample
    Charcot Marie Tooth Disease Panel Test Code D4037 Test Summary This test analyzes 62 genes that have been associated with Charcot Marie Tooth Disease. Turn-Around-Time (TAT)* 3 - 5 weeks Acceptable Sample Types Whole Blood (EDTA) (Preferred sample type) DNA, Isolated Dried Blood Spots Saliva Acceptable Billing Types Self (patient) Payment Institutional Billing Commercial Insurance Indications for Testing This panel may be appropriate for individuals with a clinical suspicion of Charcot Marie Tooth Disease and/or for indiviudals with a family history of Charcot Marie Tooth Disease. Test Description this test analyzes 62 genes that have been associated with Charcot Marie Tooth Disease disorders. Both sequencing and deletion/duplication (CNV) analysis will be performed on the coding regions of all genes included (unless otherwise marked). All analysis is performed utilizing Next Generation Sequencing (NGS) technology. CNV analysis is designed to detect the majority of deletions and duplications of three exons or greater in size. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. All variants are classified according to ACMG guidelines. Condition Description Charcot Marie Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs and hands. Charcot Marie Tooth usually becomes apparent in adolescence or early adulthood. There are several different types of Charcot Marie Tooth which are differentiated by their effects on nerve cells and patterns of inheritance.
    [Show full text]
  • Regional Collapsing of Rare Variation Implicates Specific Genic Regions
    bioRxiv preprint doi: https://doi.org/10.1101/375774; this version posted July 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Regional Collapsing of Rare Variation Implicates 2 Specific Genic Regions in ALS 3 4 Sahar Gelfman1, Sarah Dugger1, Cristiane de Araujo Martins Moreno2, 5 Zhong Ren1, Charles J. Wolock1, Neil A. Shneider2,3, Hemali Phatnani1,2,4, 6 Elizabeth T. Cirulli5, Brittany N. Lasseigne6, Tim Harris7, Tom Maniatis8, 7 Guy A. Rouleau9, Robert H. Brown Jr.10, Aaron D. Gitler11, Richard M. 8 Myers6, Slavé Petrovski12, Andrew Allen13, Matthew B. Harms1,2,3¥* and 9 David B. Goldstein1,14¥* 10 11 1Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, 12 NY, 10032, USA 13 2Department of Neurology, Columbia University Irving Medical Center, New York, NY 14 10032 USA 15 3Motor Neuron Center, Columbia University Irving Medical Center, New York, NY 10032 16 USA 17 4New York Genome Center, New York, NY 10013 USA 18 5Human Longevity INC, San Diego, CA 92121 USA 19 6HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806 USA 20 7SV Health Investors, Boston, MA 02108 USA 21 8Department of Biochemistry and Molecular Biophysics, Columbia University Irving 22 Medical Center, New York, NY 10032 USA 23 9Department of Neurology and Neurosurgery, McGill University, Montreal, H3A 2B4 24 Canada 25 10Department of Neurology, University of Massachusetts Medical School, Worcester, 26 MA 01655 USA 27 11Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305 28 USA bioRxiv preprint doi: https://doi.org/10.1101/375774; this version posted July 24, 2018.
    [Show full text]